Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b Polysaccharide-Protein Conjugate Antigens (None)
- Target
- None
- Molecular classification
- Polysaccharide, Protein, Conjugate Vaccine
01
Overview
Haemophilus influenzae type b (Hib) polysaccharide-protein conjugate antigens are the active components in Hib conjugate vaccines, designed to prevent invasive diseases caused by H. influenzae type b. The key antigenic component is the capsular polysaccharide of Hib—polyribosylribitol phosphate (PRP)—which is covalently linked to a carrier protein (e.g., tetanus toxoid, diphtheria toxoid) to enhance immunogenicity and induce a T-cell dependent immune response.
- Other names
- Hib conjugate antigensPRP-DHbOCPRP-OMPPRP-TPolyribosylribitol phosphate (PRP)Hib capsular polysaccharide
02
Mechanism of action
Induction of anti-PRP IgG antibodies via T-cell dependent immune response
03
Biological functions
Antigen presentationImmune response inductionAntibody productionB cell activationT cell activationImmunological memory generation
04
Disease associations
Prevention of Haemophilus influenzae type b infectionsPrevention of meningitisPrevention of epiglottitisPrevention of pneumoniaPrevention of septic arthritis
05
Safety considerations
Common vaccine side effects (e.g., fever, injection site reactions)
06
Interacting drugs
ActHIB
2 more in the full profile.
07
Biomarkers
Anti-capsular IgG antibody titers (>= 1.0 mcg/mL indicative of long-term immunity)
Beyond the preview
Go deeper on Haemophilus influenzae type b Polysaccharide-Protein Conjugate Antigens (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b Polysaccharide-Protein Conjugate Antigens (None).